-
In a retrospective review of 267 patients evaluated at M.D. Anderson Cancer Center with apparent early-stage, node-negative breast cancer, 15% were found to harbor "occult" metastases upon more intensive scrutiny of the axillary node specimens. In this series, long-term follow-up indicates that such discovery was not associated with a greater frequency of recurrence or poorer survival.
-
In a small, single-institutional, prospective, randomized, placebo-controlled trial, 14 eligible patients (median age 47 years) with clinical and radiographic evidence of radiation necrosis secondary to prior head-and-neck or CNS irradiation were randomized to receive intravenous saline of bevacizumab at 3-week intervals. Patients were followed with serial MRI scans, neurologic examinations, and formal neuropsychological examinations.
-
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
A 61-year-old small business owner was seen in consultation for advice regarding management of a newly discovered pulmonary mass. Seven years previously, he had a 3.5 cm moderately differentiated adenocarcinoma of the sigmoid colon resected along with four regional nodes, all of which were negative for metastatic involvement.
-
-
This randomized Phase 3 clinical trial found that adding cetuximab to standard mFOLFOX6 adjuvant chemotherapy did not improve either overall survival or disease-free survival in patients with resected stage III colon cancer, including those with wild-type KRAS tumors.
-
-
In a meta-analysis of current observational (both case-control and prospective cohort) studies evaluating the potential association between type 2 diabetes mellitus and the incidence of hematological malignancy, an increased risk for non-Hodgkin lymphoma and leukemia was demonstrated as well as a trend toward an increased risk for myeloma. Confounding factors such as age, obesity, smoking, and alcohol (risks for both diabetes and malignancy) could not be completely accounted for in such an analysis.
-
Azithromycin and cardiac risk; warfarin and heart failure; aspirin and VTE; effectiveness of long-acting contraceptives; and FDA actions.
-
This randomized, placebo-controlled, Phase 3 clinical trial showed that the majority of patients treated with pegfilgrastim experience bone pain, and that taking 500 mg of naproxen twice a day decreases its incidence and severity.